6results about How to "Good clinical applicability" patented technology

The preparation process of the eczema cream comprises the following steps: S1, raw material pretreatment: coarsely crushing calcined calamine; removing impurities from cortex phellodendri, coarsely crushing, and removing impurities from indigo naturalis for later use; mixing the three components, performing superfine grinding, and sieving with a 100-mesh sieve to obtain a medicinal powder raw material; s2, substrate preparation: melting and stirring beeswax and sesame oil at 85-90 DEG C, and cooling to obtain a transparent substrate; s3, mixing and forming: mixing the medicinal powder raw materials and the transparent matrix according to the mass ratio of (2.07-1): 2.13, uniformly stirring at 85-90 DEG C, cooling, solidifying, sterilizing and packaging to obtain the eczema cream. According to the standardized preparation process and the quality inspection method of the eczema cream, by optimizing superfine grinding parameters, a matrix ratio and a quality control system, stable production and quality controllability of the eczema cream are achieved, and technical support is provided for preparation conversion.

This invention provides a low-latency infusion sensing alarm module, system, and application control. Through innovative composite sensing technology, TDMA low-latency communication architecture, and end-edge-backend three-level linkage mechanism, it completely solves the pain points of existing technologies, realizes fully automatic unattended monitoring and accurate alarm of clinical infusion, ensures medical safety, and reduces the burden on nurses, patients, and caregivers throughout the entire process.

This invention discloses an utpatinib sustained-release tablet and its preparation method, characterized by comprising the active ingredient utpatinib and excipients, wherein the excipients include filler 1, filler 2, a matrix material, a lubricant, a flow aid, and a coating material; filler 1 is a combination of different types of microcrystalline cellulose, filler 2 is mannitol or lactose, and the matrix material is a mixture of polyvinyl acetate and povidone (Kollidon® SR). The formulation prepared by this invention solves the degradation problem encountered in the preparation of utpatinib sustained-release tablets, simplifies the production steps and facilitates commercial production, and also solves the problem of utpatinib relying on pH adjusters to enhance solubility, and has good stability and high mixing uniformity.

This invention discloses a nebulization device for traditional Chinese medicine (TCM) internal medicine, belonging to the field of medical device technology. It includes a mask assembly, a main nebulizer assembly, and a control panel. The mask assembly is detachable and connects to the main nebulizer assembly, while the control panel centrally controls all components. The mask assembly features a negative pressure suction structure. The main nebulizer assembly integrates an nebulizer, a pressurization chamber assembly, a pump assembly with a conical filter head, and an air supply assembly. A heating element is built into the connecting pipe, and a one-way valve is installed at the pipe connection. The pump rollers are covered with rubber pads. This device features a securely fixed mask, fine and thorough atomization of the medication, and can assist in medication delivery and heating. It is suitable for different patients, and its modular design facilitates cleaning and maintenance, improving medication efficacy and patient experience, thus meeting the clinical needs of TCM internal medicine nebulization.

This invention provides a control suture reel, a suture hole handle, and a ligator, relating to the field of medical device technology. The control suture reel rotates in a first direction to wind up the suture and drive the working part. It has at least one locking part circumferentially, each locking part comprising a trigger locking position and a pre-tensioning locking position arranged sequentially in opposite directions: when the trigger locking position is locked, the corresponding ligature loop is released; when the pre-tensioning locking position is locked, the suture is wound up and tensioned. This dual-locking structure achieves physical separation and timing control of tensioning and triggering, eliminating redundant bending, restoring the straightness of the release suture, and avoiding obstruction of vision and tissue adhesion. The pre-tensioning stage provides disturbance-free correction of the suture posture, and the triggering stage initiates with low inertia, significantly suppressing mechanical tissue damage caused by vibration and slippage. It improves the reliability, safety, and ergonomics of multi-turn sequential release, meeting the needs of high-precision, low-invasive endoscopic interventional treatment.

The application belongs to the field of biology and particularly relates to a composition of a biosensor for detecting APE1, a working solution and a product, the composition comprising a double-stranded promoter, an H1 hairpin, an H2 hairpin and an FQ reporter molecule, the double-stranded promoter comprising a promoter I and a blocking chain B, and the FQ reporter molecule comprising a RepF chain and a RepQ chain, the biosensor formed by the composition of the application has high sensitivity and strong specificity for detecting APE1.